interleukin 1 receptor accessory protein like 1Genealiases: IL-1-RAPL-1 · IL-1RAPL-1 · IL1R8 · IL1RAPL · IL1RAPL-1 · MRX10
Q-omics provides the consensus-scored IL1RAPL1 profile across patient tissues and cancer cell-line models. IL1RAPL1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, IL1RAPL1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, IL1RAPL1 RNA expression shows 15,320 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, BLCA, and GBM as cancer lineages where IL1RAPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL1RAPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL1RAPL1 survival associations across molecular data types. IL1RAPL1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL1RAPL1 RNA expression–survival associations across cancer types. High IL1RAPL1 expression shows unfavorable associations in BLCA and STAD, but favorable associations in UCS, UVM, BRCA and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for IL1RAPL1 RNA expression.
This table summarizes IL1RAPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for IL1RAPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL1RAPL1 shows lower tumor expression in BLCA, COAD, THCA, READ, BRCA and UCEC. The BLCA box plot shows higher IL1RAPL1 RNA expression in normal versus tumor tissue (log2 FC = −0.473, t-test p < 0.001).
This table shows molecular features associated with IL1RAPL1 in patient tissues and cancer cell lines. In patient samples, IL1RAPL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL1RAPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
